Skip to content

Merz Aesthetics

Merz Aesthetics is the medical-aesthetics business of the family-owned Merz Group and the principal commercial context for Radiesse. Radiesse entered the Merz portfolio through the 2010 acquisition of BioForm Medical. Current US regulatory and IFU records identify Merz North America in applicant and manufacturer roles.

FieldMerz Aesthetics
Core Injectable Index brandRadiesse
Material relationshipCaHA
Parent contextMerz Group
OwnershipFamily-owned and independent
Group headquartersFrankfurt am Main, Germany
Relevant US entityMerz North America, Inc.

Merz describes itself as a global family-owned company, while Merz Aesthetics operates as its dedicated medical-aesthetics business (About Merz 🔗; Merz Aesthetics 🔗).

ProductCommercial portfolioProduct originCurrent US applicantManufacturer evidence
RadiesseMerz AestheticsEntered Merz through BioForm Medical acquisitionMerz North America, Inc. in current FDA PMA recordsMerz North America, Inc. in reviewed IFUs
Radiesse (+)Merz AestheticsSame Radiesse franchise with lidocaine-containing presentationMerz North America, Inc.Merz North America, Inc. in reviewed IFUs

This table is US-centered where it names applicant or manufacturer. Other markets can identify local importers, distributors, authorized representatives, or approval holders.

Merz’s corporate history records the 2010 acquisition of BioForm Medical and its flagship product Radiesse (Merz history 🔗).

This history matters because older:

  • studies
  • regulator records
  • IFUs
  • safety reports
  • corporate announcements

may use BioForm rather than Merz. A historical BioForm source is not necessarily outdated clinically, but the company relationship should be placed on a timeline.

The FDA PMA database names Merz North America as applicant for current Radiesse supplements, including the March 31, 2026 décolleté indication expansion (FDA PMA history 🔗).

A reviewed Merz IFU identifies Merz North America as manufacturer of Radiesse (Merz IFU 🔗).

Use the exact regional IFU before extending these roles globally.

Merz Aesthetics’ broader portfolio includes injectables, devices, and skincare. For the Collagen Stimulators cluster, Radiesse is the relevant anchor.

Other Merz products should appear only when they clarify:

  • combination portfolio structure
  • company identity
  • a specific comparison
  • regulatory or commercial relationships

Do not add unrelated Merz products merely to make the company page appear comprehensive.

DateEventWhy it changes interpretation
1908Merz founded in FrankfurtEstablishes family-company origin
2010Merz acquired BioForm Medical and RadiesseExplains the transition from legacy BioForm sources to Merz ownership
2020Merz established independently operating Aesthetics, Therapeutics, and Consumer Care businessesClarifies the present business-unit structure
March 31, 2026FDA expanded Radiesse indication to 1:2 diluted décolleté useAdds a current product-specific US regulatory milestone

Do not use Merz Aesthetics’ portfolio position to infer:

  • that every CaHA product is Radiesse
  • one universal Radiesse indication
  • that Radiesse (+) and Radiesse are identical
  • that diluted CaHA techniques are approved across all anatomies
  • that family ownership changes product-level evidence
  • Regional regulation separates Merz’s US applicant role from European conformity and Korean intended-use evidence.
  • Radiesse contains formulation, variant, dilution, and FDA-indication detail.
  • CaHA explains the microsphere and carrier distinction.
  • Sinclair provides a company comparison with multiple collagen-stimulator materials.
  • Collagen Stimulators maps the wider company graph.